Positive Effects of Oral Antibiotic Administration in Murine Chronic Graft-Versus-Host Disease.
Administration, Oral
Allografts
Animals
Anti-Bacterial Agents
/ pharmacology
Bone Marrow Transplantation
Chronic Disease
Female
Graft vs Host Disease
/ drug therapy
Interleukin-6
/ immunology
Macrophages
/ immunology
Mice
Mice, Inbred BALB C
T-Lymphocytes, Regulatory
/ immunology
Th17 Cells
/ immunology
antibiotics
dry eye disease
gentamicin
graft-vs-host disease
microbiome
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Apr 2021
03 Apr 2021
Historique:
received:
26
02
2021
revised:
26
03
2021
accepted:
31
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
14
5
2021
Statut:
epublish
Résumé
Chronic graft-versus-host disease (cGVHD) is one of the most frequent complications experienced after allogeneic hematopoietic stem cell transplantation. Reportedly, dysbiosis and severe damage to the microbiome are also closely associated with GVHD. Herein, we aimed to elucidate the positive and negative effects of the administration of various antibiotics in a murine model of cGVHD. For allogeneic bone marrow transplantation (allo-BMT), bone marrow from B10.D2 mice were transplanted in BALB/c mice to induce cGVHD. The cGVHD mice were orally administered ampicillin, gentamicin (GM), fradiomycin, vancomycin, or the solvent vehicle (control group). Among the antibiotic-treated mice, the systemic cGVHD phenotypes and ocular cGVHD manifestations were suppressed significantly in GM-treated mice compared to that in control mice. Inflammatory cell infiltration and fibrosis in cGVHD-targeted organs were significantly attenuated in GM-treated mice. Although regulatory T cells were retained at greater levels in GM-treated mice, there were significantly fewer Th17 cells and interleukin (IL)-6-producing macrophages in cGVHD-targeted organs in these mice. Collectively, our results revealed that orally administered GM may exert positive effects in a cGVHD mouse model.
Identifiants
pubmed: 33916809
pii: ijms22073745
doi: 10.3390/ijms22073745
pmc: PMC8038334
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Interleukin-6
0
interleukin-6, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Biol Blood Marrow Transplant. 2016 Oct;22(10):1765-1772
pubmed: 27492793
Ocul Surf. 2017 Jul;15(3):366-403
pubmed: 28736338
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES71-DES79
pubmed: 30481809
Blood. 2019 Dec 5;134(23):2092-2106
pubmed: 31578204
J Infect Dis. 1991 Nov;164(5):917-21
pubmed: 1940469
Bone Marrow Transplant. 2011 Sep;46(9):1226-30
pubmed: 21057549
Radiat Res. 1971 Mar;45(3):577-88
pubmed: 4396814
Nature. 2013 Jul 4;499(7456):97-101
pubmed: 23803760
J Hyg (Lond). 1974 Oct;73(2):197-203
pubmed: 4528886
Oncoimmunology. 2016 Dec 27;6(1):e1258506
pubmed: 28197380
Nature. 2006 May 11;441(7090):235-8
pubmed: 16648838
J Immunol. 2002 Mar 15;168(6):3088-98
pubmed: 11884483
Can J Vet Res. 2010 Jan;74(1):1-10
pubmed: 20357951
Lancet. 2009 May 2;373(9674):1550-61
pubmed: 19282026
Br J Ophthalmol. 1999 Oct;83(10):1125-30
pubmed: 10502571
J Innate Immun. 2019;11(5):405-415
pubmed: 30286447
Cell Mol Life Sci. 2019 Feb;76(3):473-493
pubmed: 30317530
PLoS One. 2014 May 21;9(5):e97921
pubmed: 24848115
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1800-1808
pubmed: 28516469
Blood. 2020 Jul 2;136(1):130-136
pubmed: 32430495
FEBS Open Bio. 2017 Aug 16;7(9):1316-1327
pubmed: 28904861
Biol Blood Marrow Transplant. 2017 May;23(5):820-829
pubmed: 28192251
Antimicrob Agents Chemother. 2014;58(4):1972-6
pubmed: 24419337
Blood. 2014 Aug 14;124(7):1174-82
pubmed: 24939656
Science. 2013 Aug 2;341(6145):569-73
pubmed: 23828891
Sci Rep. 2016 Apr 18;6:23561
pubmed: 27087247
J Int Med Res. 2020 Jun;48(6):300060520925693
pubmed: 32527171
Bone Marrow Transplant. 2012 Nov;47(11):1470-3
pubmed: 22484321
N Engl J Med. 2017 Dec 28;377(26):2565-2579
pubmed: 29281578
Bone Marrow Transplant. 2017 Feb;52(2):183-190
pubmed: 27526283
Front Microbiol. 2020 Jul 22;11:1642
pubmed: 32793150
FASEB J. 2020 Aug;34(8):10778-10800
pubmed: 32619061
Front Immunol. 2017 Jun 08;8:667
pubmed: 28642760
Ocul Surf. 2020 Apr;18(2):335-344
pubmed: 31644955
Cancer Discov. 2017 May;7(5):522-538
pubmed: 28202625
J Immunol. 2014 Sep 1;193(5):2565-73
pubmed: 25080485
Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):923-8
pubmed: 26968719
PLoS One. 2019 May 9;14(5):e0215130
pubmed: 31071120
Nat Rev Cancer. 2018 May;18(5):283-295
pubmed: 29449660
Immunity. 2014 Apr 17;40(4):594-607
pubmed: 24684957
Am J Pathol. 2009 Dec;175(6):2372-81
pubmed: 19893038
PLoS One. 2013 Jun 06;8(6):e64724
pubmed: 23762250
Cornea. 2015 Nov;34 Suppl 11:S142-52
pubmed: 26448172
J Proteome Res. 2013 Jun 7;12(6):2987-99
pubmed: 23631562
Nat Med. 2019 Aug;25(8):1234-1242
pubmed: 31332389
N Engl J Med. 1983 Feb 10;308(6):302-7
pubmed: 6337323
Invest Ophthalmol Vis Sci. 2015 May;56(5):3149-58
pubmed: 26024098
Blood. 1996 Oct 15;88(8):3230-9
pubmed: 8963063
Korean J Hematol. 2011 Jun;46(2):80-7
pubmed: 21747879
Curr Opin Hematol. 2011 Nov;18(6):414-20
pubmed: 21912257
Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5416-25
pubmed: 22786901
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1079-86
pubmed: 17325149
J Natl Cancer Inst. 1974 Feb;52(2):401-4
pubmed: 4150164
Cell Host Microbe. 2018 Apr 11;23(4):447-457.e4
pubmed: 29576480
Science. 2019 Nov 29;366(6469):1143-1149
pubmed: 31780560
Blood. 1999 May 15;93(10):3267-75
pubmed: 10233878
Elife. 2016 Jan 26;5:e09394
pubmed: 26809474